‌

US Patent 10940148 Combination therapy with glutaminase inhibitors and immuno-oncology agents

Patent 10940148 was granted and assigned to Calithera Biosciences on March, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Calithera Biosciences

0

Current Assignee

Calithera Biosciences

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Susan M. Molineaux0

Mark K. Bennett0

Matthew I. Gross0

Susan D. Bromley0

Francesco Parlati0

Date of Patent

March 9, 2021

0

Patent Application Number

162655290

Date Filed

February 1, 2019

0

Patent Citations

US Patent 10676472 Crystal forms of glutaminase inhibitors

US Patent 10258619 Combination therapy with glutaminase inhibitors and immuno-oncology agents

US Patent 10278968 Combination therapy with glutaminase inhibitors

US Patent 10316030 Crystal forms of glutaminase inhibitors

0

US Patent 10441587 Treatment of lung cancer with inhibitors of glutaminase

US Patent 10793535 Heterocyclic glutaminase inhibitors

Patent Primary Examiner

Shawquia Jackson

0

Patent abstract

The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10940148 Combination therapy with glutaminase inhibitors and immuno-oncology agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.